Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress
Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc.
Perspective Therapeutics Inc. (CATX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 183,342 | $764,536 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.03 | 11,000 | $22,294.80 | 59,800 | 2025-11-13 | Filing | |
| $2.10 | 9,498 | $19,945.80 | 9,864 | 2025-11-12 | Filing | |
| $2.21 | 4,650 | $10,288.13 | 4,650 | 2025-03-28 | Filing | |
| $2.24 | 22,026 | $49,384.49 | 59,383 | 2025-03-28 | Filing | |
| $2.14 | 38,145 | $81,775.25 | 108,982 | 2025-03-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.53 | 13,340 | $20,410.20 | 0 | 2015-04-02 | Filing | |
| $2.54 | 25,000 | $63,560.00 | 0 | 2014-06-10 | Filing | |
| $2.27 | 25,000 | $56,750.00 | 0 | 2014-06-03 | Filing | |
| $2.22 | 30,571 | $67,867.62 | 0 | 2014-05-27 | Filing | |
| $2.22 | 30,571 | $67,867.62 | 0 | 2014-05-27 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,378,956 | $18,260,247 | 0% | |
| 2. | 1,618,993 | $6,751,201 | 3.93% | |
| 3. | 910,221 | $3,795,621 | 0% | |
| 4. | 872,200 | $3,637,074 | 0.18% | |
| 5. | 752,033 | $3,135,978 | 0% |
News See All
11 Best High Return Penny Stocks to Buy Right Now
Small-cap companies are in the spotlight amid market rotation away from technology heavyweights clobbered by premium valuation.
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial
Perspective Therapeutics, Inc.
13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
10 Best Multibagger Stocks To Buy Heading into 2025
November has been an eventful month so far for the market as the Fed cut rates by a quarter percentage and president-elect, Donald Trump won the election for the second time.
10 Small Cap Stocks with High Potential
As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for interest rate cuts and the consequent impacts on stock and bond performances, investors are...
Hedge Fund Resource Center